Camp4 Therapeutics Corp
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
CAMP$4.33-7.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Cash Flows for the
Unaudited Condensed Consolidated Statements of Cash Flows
(In thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities | ||
| Net loss | $(40,119) | $(38,512) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 1,267 | 1,278 |
| Stock-based compensation expense | 2,847 | 3,235 |
| Change in fair value of derivative tranche liability | 1,800 | — |
| Impairment of right-of-use asset | 494 | — |
| Loss on the sale of property and equipment | 67 | — |
| Non-cash lease expense | 1,443 | 1,285 |
| Non-cash interest and other expenses | 17 | 68 |
| Change in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (109) | (343) |
| Accounts payable | (561) | 1,024 |
| Accrued expenses and other liabilities | (393) | (310) |
| Deferred revenue | (385) | — |
| Operating lease assets and liabilities | (2,214) | (1,999) |
| Net cash used in operating activities | (35,846) | (34,274) |
| Investing activities | ||
| Purchases of property and equipment | (279) | (178) |
| Proceeds from the sale of property and equipment | 36 | — |
| Net cash used in investing activities | (243) | (178) |
| Financing activities | ||
| Proceeds from issuance of common stock and pre-funded warrants, net | 32,562 | — |
| Proceeds allocated to the derivative tranche liability | 14,930 | — |
| Proceeds from exercise of stock options | 3 | 33 |
| Principal payments on finance leases | (93) | (268) |
| Principal payments on financing obligation | (97) | (345) |
| Payments of deferred offering costs | — | (820) |
| Net cash provided by (used in) financing activities | 47,305 | (1,400) |
| Net change in cash, cash equivalents, and restricted cash | 11,216 | (35,852) |
| Cash, cash equivalents and restricted cash – beginning of year | 65,663 | 40,004 |
| Cash, cash equivalents and restricted cash – end of period | $76,879 | $4,152 |
| Supplemental disclosures of cash flow information: | ||
| Finance lease right-of-use asset converted to fixed asset | $290 | $— |
| Issuance costs in accounts payable and accrued expenses | $230 | $— |
| Deferred offering costs in accounts payable and accrued expenses | $— | $2,504 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.